Dexmedetomidine Versus Lidocaine in Attenuating Airway Reflexes During Recovery of Thyroidectomy Patients

NCT05657028 | Unknown

• 1 other identifier: attenuating airway reflexes
• Study Type: interventional
• Target: 140
• Locations: 1 country
• Sites: 1

Brief Summary

It is widely believed that most of the patients experience a cough upon emergence from general anesthesia, due to many causes including the presence of an endotracheal tube, uncleared secretions and anesthetic gas. Cough during tracheal extubation may lead to several complications, such as hypertension, tachycardia and postoperative bleeding. In this study the investigators are going to compare the effectiveness of intravenous Dexmedetomidine and intravenous lidocaine in attenuating the air way reflexes and coughing during recovery of thyroidectomy patients.

Conditions

Anesthesia; Airway Complication of Anesthesia

Outcome Measures

Primary Outcomes (1)

• compare effectiveness of Dexmedetomidine and intravenous lidocaine in attenuating cough reflex during the tracheal extubation period after thyroid surgery

  the investigators use the following cough score where 0 = no cough, 1 = minimal (single) cough, 2 = moderate (≤5 seconds) cough and 3 = severe (\>5 seconds) cough to reflect the degree of attenuation of air way reflexes for each group

  5 minutes from extubation

Study Arms (2)

Group D (Dexmedetomidine)

EXPERIMENTAL

In the Dexmedetomidine group, patients will be given IV bolus infusion of dexmedetomidine

Drug: Dexmedetomidine

Group L (Lidocaine)

EXPERIMENTAL

In the Lidocaine group, the patients will be given an IV bolus infusion of lidocaine

Drug: Lidocaine IV

Interventions

Dexmedetomidine DRUG

-In the Dexmedetomidine group, patients will be given IV bolus infusion of dexmedetomidine 0.5 μg/kg over 10 min before induction of anesthesia, followed by a continuous IV infusion of dexmedetomidine 0.4 μg/kg/hour until 30 min before the end of surgery.

Group D (Dexmedetomidine)

Lidocaine IV DRUG

In the Lidocaine group, the patients will be given an IV bolus infusion of lidocaine (2%)1.5mg/kg over 10 min before induction of anesthesia, followed by a continuous IV infusion of lidocaine 1.5 mg/kg /hour until 30 min before the end of surgery.

Group L (Lidocaine)

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients scheduled for elective thyroidectomy surgery.
• Age: patients between 18-and 65-years old from both sexes.
• Classified as either American Society of Anesthesiologists (ASA) class I or II.

You may not qualify if:

• Refusal of procedure or participation in the study.
• Patients suffering from asthma, chronic cough, preoperative upper respiratory infection symptoms.
• Current smoker.
• Medication involving angiotensin-converting-enzyme inhibitors (ACE-I).
• Classified as either American Society of Anesthesiologists (ASA) class III or IV.
• Sinus Bradycardia (\<60/min) or history of any type of heart block or Beta-Blockers medication.

Sponsors & Collaborators

• Ain Shams University: lead

Study Sites (1)

Ainshams University Hospitals

Cairo, 11511, Egypt

RECRUITING

Related Publications (1)

• Hu S, Li Y, Wang S, Xu S, Ju X, Ma L. Effects of intravenous infusion of lidocaine and dexmedetomidine on inhibiting cough during the tracheal extubation period after thyroid surgery. BMC Anesthesiol. 2019 May 4;19(1):66. doi: 10.1186/s12871-019-0739-1.

  PMID: 31054568 RESULT

MeSH Terms

Interventions

Dexmedetomidine

Intervention Hierarchy (Ancestors)

Imidazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Central Study Contacts

Ola N Hussain Zaher, MSC

CONTACT

+201003067762; ano_triple@hotmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 8, 2022
• First Posted: December 20, 2022
• Study Start: September 1, 2022
• Primary Completion: January 1, 2024
• Study Completion: September 1, 2024
• Last Updated: February 1, 2023

Record last verified: 2023-01

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)